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Original Article
Cardiac radiation dose distribution, cardiac events and mortality 
in early-stage lung cancer treated with stereotactic body radiation 
therapy (SBRT)
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Background: The impact of radiation dose to the heart in early-stage lung cancer patients treated with 
definitive stereotactic body radiation therapy (SBRT) is not well known. We, therefore, analyzed whether 
higher radiation dose to the heart would lead to an increase in cardiac toxicity and overall mortality.
Methods: Seventy-four patients with 75 tumors treated definitively with SBRT for early-stage non-small 
cell lung cancer (NSCLC) and two cases of limited-stage small cell lung cancer (SCLC) with an average 
follow-up of 35 months (range, 1–130 months) were retrospectively analyzed. The whole heart and cardiac 
substructures including atria, ventricles, heart valves, atrioventricular (AV) node and four major coronary 
artery branches were contoured using commercial treatment planning software. For each structure, multiple 
dose-volume parameters were recorded. The relation between radiation doses to the heart, tumor location, 
and preexisting medical conditions with the development of cardiac events and mortality was assessed. 
Results: Overall, there was large variability in dose to cardiac substructures: mean heart dose (MHD) 
averaged 1.90 Gy (range, 0.04–11.00 Gy) equivalent 2 Gy dose (EQD2) and average max dose to the left 
anterior descending artery (LAD) was 5.67 Gy (range, 0.04–48.60 Gy) EQD2. Patients with tumor location 
in the upper lobes received higher cardiac radiation dose compared to other lobes (P<0.0001). There was no 
difference in MHD between central and peripheral tumor locations. The distance between heart and tumor 
was negatively associated with MHD (r=−0.61, P<0.0001). Eighteen patients developed cardiac complications 
including the need for defibrillator placement, arrhythmia development and worsening heart failure. 
Preexisting cardiac disease was associated with an increased number of cardiac events after radiotherapy 
(P=0.039). However, neither radiation dose to the whole heart or the cardiac substructures, nor comorbidities 
such as diabetes, hypercholesterolemia, hypertension or COPD were associated with the number of cardiac 
events or overall mortality.
Conclusions: Radiation doses to the heart and its substructures show large variability. Cardiac events 
occurred more frequently in patients with a history of heart problems. At present, the effect of radiation dose 
on cardiac toxicity is unclear in patients undergoing SBRT for early-stage lung cancer. Longer follow-up and 
a larger cohort are needed to assess for late cardiac sequelae. 
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Introduction
Radiation dose to the heart has been associated with 
cardiovascular mortality and cardiac complications 
predominantly in long term survivors with breast cancer (1-3), 
Hodgkin’s lymphoma (4) and pediatric malignancies (5). 
Cardiac toxicity appears to be dependent on the radiation 
dose and radiation technique (1,6,7). Radiation therapy dose 
to various cardiac substructures has been associated with 
coronary artery, pericardial, and conduction system diseases 
as well as cardiomyopathy (8). For breast cancer, the 
radiation dose distribution to various heart regions has been 
well-described (9). In addition, a recent study demonstrated 
a clinically-relevant dose-effect relationship between mean 
heart dose (MHD), left ventricle volume receiving 5 Gy and 
acute coronary events (6).
Recently, interest in cardiac toxicity in lung cancer patients 
has increased (10). Several studies showed that radiation dose 
to the heart in stage III lung cancer patients was associated 
with the development of cardiac events (7,11-15) and overall 
survival (12,14,15). Importantly, RTOG 0617 showed 
that the heart volume receiving ≥5 and 30 Gy predicted 
overall survival. While cardiac toxicity is usually a late 
event, cardiotoxicity has also been observed early after 
radiotherapy (11). Because of this, it is important to 
investigate earlier time points in addition to the late ones. 
Cardiotoxicity in patients treated with SBRT for early-stage 
lung cancer delivering higher doses per fraction to smaller 
subvolumes depending on the individual tumor location has 
not been studied in great detail. In this setting, patients who 
are inoperable or who choose not to undergo surgery are 
treated with radiation therapy. Patients with early-stage lung 
cancer have a better prognosis than locally-advanced lung 
cancer patients (16) and thus are more likely to survive to 
experience cardiac toxicity. Still, despite good locoregional 
tumor control and a moderate prevalence of distant 
metastases, 5-year survival rates of 41.2% are surprisingly 
low indicating that factors other than tumor contribute to 
high mortality rates (17). Two retrospective studies recently 
investigated cardiac dose as a predictor of mortality in 
early-stage lung cancer stereotactic body radiation therapy 
(SBRT). While one study found no relation between 
mean dose for the whole heart and survival (18), the other, 
larger study observed that radiotherapy doses mainly to 
the upper regions of the heart were associated with non-
cancer death (19). Our study aims to provide a more 
detailed analysis than what is currently available on cardiac 
dose and patient outcomes after SBRT. We investigate in 
particular the association of radiation therapy doses to the 
heart and its multiple substructures with cardiac events and 
overall survival. In addition, we also analyze the influence 
of preexisting cardiac disease and other comorbidities with 
respect to the development of cardiac events and survival.
Methods
Aim, design and setting
Seventy-four patients with 75 tumors treated definitively 
with SBRT for stage I or II non-small cell lung cancer 
(NSCLC) (72 cases) and small cell lung cancer (SCLC) 
(2 cases) at our institution were retrospectively analyzed 
on an IRB-approved protocol (VCU IRB HM15356). 
Information was gathered from electronic medical records. 
Following radiotherapy, patients returned for regular 
follow-up visits that included clinical history, physical exam 
and computed tomography imaging every 3 months for the 
first 2 years, then every 6 months up to 5 years, and yearly 
afterwards. Patients were seen by cardiologists as clinically 
indicated. All available medical records from all specialties 
were utilized for this study. The relation between radiation 
doses to the heart and cardiac substructures, tumor location, 
and preexisting medical conditions with the development of 
cardiac events and mortality was assessed. Any new cardiac 
conditions that occurred after radiotherapy were recorded 
as cardiac events. These included diseases of the cardiac 
conduction system, structural heart disease, heart failure 
and ischemic cardiac disease.
Patient characteristics
Patients were treated definitively with lung SBRT 
between 2007 and 2017. All of these patients were medical 
inoperable or refused surgery. Chemotherapy or surgery 
were not utilized. Seventy-seven percent of patients 
received 48 Gy in 4 fractions. Other doses ranged from 
40 Gy in 4 fractions to 60 Gy in 8 fractions. The average 
follow-up was 35 months, median was 27 months, ranging 
from 1 month to 10 years and 10 months. Sixty-one (82%) 
of patients were treated for newly diagnosed lung cancer 
and 13 (18%) were treated for lung cancer recurrence. All 
recurrences were treated initially with surgery except for 
three cases which were treated with radiochemotherapy. All 
patients who underwent thoracic radiation therapy prior to 
SBRT of lung cancer had negligible heart doses. Details of 
patient characteristics including preexisting cardiac disease 
2348
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(4):2346-2356jtd.amegroups.com
Reshko et al. Early-stage lung cancer SBRT radiation dose distribution, cardiac events and mortality
and comorbidities are described in Table 1. Note that all 
patients with hyperlipidemia, diabetes and hypertension 
were included in the studies whether the diseases were 
medically controlled or not. 
Further treatment information is listed in Table 2 and 
details of cardiac conditions are listed in Table 3. Patients 
were included in this analysis if they had a tumor located 
within 6 cm of the heart border, as larger distances resulted 
in minimal (<0.1 Gy) radiation exposure of the heart. 
The distance was recorded as the smallest distance in cm 
between the planning target volume (PTV) and heart 
border. If there was overlap between PTV and heart, then 
a negative distance was recorded. Central tumor location 
was defined as being within 2 cm of the mediastinum and 
central airways. 
Dosimetric parameters
The whole heart and cardiac substructures (13 substructures 
including 2 atria, 2 ventricles, 4 heart valves, AV node and 
four major coronary artery branches) were contoured on 
the 30% phase of the 4D treatment planning CT of each 
patient using commercial treatment planning software 
Pinnacle (Philips, The Netherlands) and MIM 6.6.10 
Table 1 Patient clinical characteristics at baseline (N=74)




Age, years Mean: 70 (range, 48–91)






























Upper right and left 42 57




Central tumor 38 51
Peripheral tumor 36 49





Total radiation dose (Gy) 49 40–60
Dose per fraction (Gy) 11 5–20
Number of fractions used 4 3–10
48 Gy in 4 fractions 57 77
Other fractionations 17 23
Technique
Static beams (3DCRT or IMRT) 31 42
VMAT 43 58
GTV (cc) 18 2–70 
PTV (cc) 44 7–170  
Distance PTV to heart (cm) 3.5 −0.9 to 6
3DCRT, 3-dimensional conformal radiotherapy; IMRT, intensity-
modulated radiation therapy; VMAT, volumetric modulated arc 
radiotherapy; GTV, gross tumor volume; PTV, planning target 
volume.
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(Cleveland, OH, USA) according to contouring atlas 
guidelines (20). For each structure, dose-volume parameters 
including mean dose, highest dose to 0.03 cm3 (D0.03cc) and 
percentage of a given structure receiving either ≥5, 10, 20, 
30, 40, 50 or 60 Gy (V5-Gy, V10-Gy …) were recorded. D0.03cc 
was used in accordance with AAPM TG 101 guidelines for 
SBRT (21). Equivalent doses of 2-Gy fractions (EQD2) 
were calculated from the dose-volume histograms as 
nd[(d+α/β)÷(2+α/β)], where n was the number of fractions, 
d was the dose to the structure per fraction (in Gy), and 
α/β was 2 Gy (22). For the patient with two tumors treated 
at the same time, the composite treatment plan was used 
to calculate the total dose to the heart structures from both 
treatments. 
Statistical analysis
Mann-Whitney U test was used to test significance of 
differences in cardiac radiation dose for tumor location, 
treatment technique, cardiac toxicity, and overall and non-
cancer survival as well as the difference in survival and 
cardiotoxicity in patients based on the number of smoking 
pack years. Pearson correlation coefficient was used to 
assess the relationship between tumor distance and PTV 
size with heart radiation dose. Chi-squared distribution and 
Kaplan-Meier estimator were calculated to determine the 
relationship between prior cardiac events, diabetes mellitus, 
hypertension, hypercholesterolemia and cardiotoxicity 
development and overall survival. All tests were done with a 
significance level of P<0.05.
Results
Dosimetry
Radiation dose distributions to various cardiac substructures 
are described in Table 4. All reported doses are expressed 
in Gy EQD2. There was considerable variability in dose 
to different cardiac substructures: MHD averaged 1.90 Gy 
(range, 0.04–11.0 Gy) and average D0.03cc to the left 
anterior descending artery (LAD) was 5.67 Gy (range 
0.04-48.8 Gy). Figure 1A,B,C,D illustrates some of the 
important dose distributions. Notably, MHD >2 Gy was 
found in 23 patients and MHD >5 Gy was observed in 
8 patients. Ten patients received a D0.03cc of 60 Gy or 
more. Patients with tumors in the upper lobes received 
higher MHD and heart D0.03cc compared to the other lobes 
(3.31 Gy versus 1.15 Gy, P<0.0001 and 41.06 Gy versus 
29.51 Gy, P=0.00034). We did not observe a significant 
difference in MHD or heart D0.03cc between central and 
peripheral location of the tumors (P=0.84 and P=0.27). 
The distance between heart and tumor was weakly 
associated with the MHD (r=−0.61 and P≤0.0001). The 
magnitude of PTV was only weakly associated with MHD 
(r=0.41, P=0.0004). Static beams (3DCRT or IMRT) 
radiation technique did not significantly differ from 
VMAT for MHD or Heart D0.03cc (P=0.61 and P=0.95). 
RTOG 0813 constraints (Heart/Pericardium <15 cc max 
dose is 32 Gy and maximum point dose is 105% of PTV 
prescription) (23) were met by all patients except for four 
cases. Of these, only one developed a cardiac event (heart 
attack) after radiation treatment. In addition, no patient 
with a distance of >5 cm between PTV edge and heart in 
this cohort had a MHD >5 Gy.
Mortality
At the time of analysis, 28 patients had died (38%), 20 of 
non-cancer related deaths (one of them of heart failure) and 
8 of cancer progression. 38 were alive (51%), 8 were lost to 
follow-up. Kaplan-Meier estimated 1-year overall survival 
was 96%, and 2-year survival was 77%. Prior cardiac 
disease, radiation dose to the whole heart or the cardiac 
substructures, number of pack years smoked, diabetes, 
COPD, hypercholesterolemia and hypertension were not 
associated with overall mortality (Figure 2A). 
Cardiac events
18 patients developed cardiac events after on average 
19 months (range, 3–60 months). The cohorts that 
developed cardiac events and those that did not, had 
comparable demographics. The most common events were 
arrhythmia development (8 cases), coronary artery disease 
(7 cases), congestive heart failure (5 cases) and one case of 
mitral valve replacement (in addition to a worsening heart 
failure). Details of cardiac events are listed in Table 3. While 
arrhythmias occurred on average at 26 months, coronary 
artery disease and heart failure occurred on average at 
15 and 13 months, respectively. Prior cardiac disease was 
associated with an increased rate of cardiac events after 
radiotherapy (14 of 42 patients with prior cardiac history 
developed cardiac events compared to 4 out of 32 patients 
with no prior history of cardiac events (odds ratio =3.5, 
P=0.039). Cardiac event-free survival was associated with 
prior cardiac disease (P=0.075, Figure 2B). Radiation dose 
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Table 4 Radiation dose to cardiac substructures (all values are 
EQD2)
Substructure Mean (Gy) Median (Gy) Range (Gy)
Whole heart
Mean dose 1.90 1.03 0.04–11.00
D0.03cc 33.38 13.10 0.15–212.22
Aortic valve
Mean dose 2.21 0.47 0.05–10.37
D0.03cc 4.04 0.74 0.07–33.47
AV node
Mean dose 1.93 0.18 0–15.19
D0.03cc 2.73 0.20 0.01–20.63
Left anterior descending 
artery
Mean dose 2.01 0.80 0.02–16.17
D0.03cc 5.67 2.30 0.04–48.60
Left atrium
Mean dose 3.38 1.62 0.06–43.47
D0.03cc 20.67 9.19 0.13–195.20
Left circumflex artery
Mean dose 3.65 0.53 0.02–35.52
D0.03cc 5.59 0.80 0.04–64.73
Left main coronary artery
Mean dose 3.03 0.51 0.05–32.73
D0.03cc 4.06 0.73 0.05–34.38
Left ventricle
Mean dose 1.47 0.20 0.02–12.02
D0.03cc 12.92 2.84 0.09–143.68
Mitral valve
Mean dose 2.39 0.18 0.01–22.79
D0.03cc 3.09 0.20 0.02–28.80
Pulmonic valve
Mean dose 2.85 0.54 0.04–33.26
D0.03cc 5.61 1.22 0.06–45.72
Right atrium
Mean dose 3.03 0.52 0.03–31.38
D0.03cc 21.37 5.76 0.07–211.47
Table 4 (continued)
Table 4 (continued)
Substructure Mean (Gy) Median (Gy) Range (Gy)
Right coronary artery
Mean dose 2.27 0.64 0.02–17.47
D0.03cc 5.53 2.55 0.03–47.91
Right ventricle 
Mean dose 1.46 0.51 0.02–9.71
D0.03cc 12.87 5.96 0.07–194.45
Tricuspid valve
Mean dose 2.02 0.16 0.02–15.04
D0.03CC 2.58 0.18 0.04–18.63
cc, cubic centimeters, D0.03cc (Gy), minimum radiation dose 
received by the highest dose 0.03 cc volume of a given structure 
expressed in Gy. 
to the whole heart or the cardiac substructures, number of 
pack years smoked, diabetes, COPD, hypercholesterolemia 
and hypertension was not associated with cardiac events 
after radiotherapy. Figure 3 illustrates that radiation dose 
distribution is similar between patients who experienced 
cardiac events and those who did not (P=0.68).
Discussion
In this study, we investigated the impact of radiation 
dose to cardiac substructures and the whole heart and the 
development of cardiac events in early-stage lung cancer 
treated with SBRT. There is evidence that radiation 
dose to certain structures of the heart contributes to the 
development of cardiac toxicity (6,15,24). However, our 
analysis did not find statistically significant correlations 
between radiation dose to the total heart or its substructures 
and overall survival or development of cardiac events. We 
observed that doses to the heart and its substructures 
show large variability among patients. As expected, 
there was an inverse correlation of radiation dose with 
the distance of the tumor from the heart, although this 
correlation was weak. Radiotherapy to centrally-located 
or large tumors did not necessarily result in higher 
cardiac dose compared to peripherally-located and 
smaller tumors. Furthermore, more advanced radiation 
treatment technology did not necessarily spare the 
heart from excessive radiation dose. While in our study 
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patients with preexisting cardiac conditions were more 
likely to develop cardiac events, patients with other 
medical comorbidities were not. These findings will add 
to the understanding of cardiac events following SBRT 
in early-stage lung cancer. 
Radiotherapy-induced cardiac toxicity
In breast, lymphoma and locally-advanced lung cancer, 
standard fractionation is typically utilized as opposed to 
SBRT which is studied here (2-4,7). High doses with SBRT 
only involve a small volume of the heart. For tumors located 
close to the heart, the dose to a small area can be fairly high. 
Because of this, exploring the dose to individual cardiac 
substructures is important (6,9). Indeed, it is currently 
unknown how much radiation dose is safe to administer 
to the heart under these circumstances (25). Higher 
radiation doses to the left ventricle (6), LAD (25) and left 
atrium (15) have been associated with an increased rate of 
post-radiotherapy cardiac events which is mainly postulated 
to be due to ischemic changes. Pericardial disease, 
conduction system disorders and cardiomyopathy have 
been identified as radiotherapy-induced cardiotoxicities 
as well, though to a lesser extent (8). If a substructure that 
is particularly sensitive to radiation therapy is identified, 
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Figure 1 Examples for radiation dose distribution. (A) Mean heart dose distribution in Gy (EQD2); (B) heart D0.03cc dose distribution in Gy 
(EQD2); (C) frequencies at which left ventricle received ≥5 Gy (EQD2); (D) left anterior descending artery (LAD) D0.03cc dose distribution 
in Gy (EQD2).
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that avoids specific substructures as much as possible (11,25). 
Cardiac toxicity following SBRT has rarely been 
reported. Only two other studies investigated radiation dose 
to the heart in early stage lung cancer treated with SBRT. 
The follow-up times in those studies were comparable to 
our report (18,19).  Tembhekar et al. show results similar to 
ours. Cardiac dose was not associated with overall survival 
in lung cancer SBRT (18). The dose-volume parameters 
of the heart in this study are comparable to ours (MHD 
1.57 Gy compared to 2.26 Gy in ours and maximum 
heart dose 14.07 Gy compared to 15.64 Gy in ours). 
The second much larger study including 803 patients by 
Stam et al. showed that maximum dose to the left atrium 
and the dose to 90% of the superior vena cava were 
significantly associated with non-cancer death (19). The 
pathophysiologic mechanism behind this observation is 
not clear (26). The dose-volume parameters of the heart 
in this report are considerably different from ours [MHD 
was 11.40 Gy (EQD2) compared to 1.90 Gy (EQD2) in 
ours and left atrium maximum dose was 6.50 Gy (EQD2) 
Figure 2 Kaplan-Meier Curves. (A) Overall survival; (B) cardiac toxicity-free survival among patients with and without prior heart disease.
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compared to 3.38 Gy (EQD2) in ours], while tumor sizes 
were similar. Stam et al. did not investigate any association 
with cardiac events. The causative relation of high doses 
with cardiac events and cardiac mortality is therefore still 
unclear. However, the present study provides more detailed 
analysis on cardiac dose and patient outcomes after SBRT 
in early-stage lung cancer. Interestingly, in our cohort no 
pericardial effusions were observed, which is commonly 
observed after radiotherapy for locally advanced lung 
cancer (14). 
Preexisting cardiac conditions
Five-year overall survival for early-stage lung cancer 
patients treated with SBRT is only 44% which underscores 
the relevance of non-cancer contributors to mortality (17). 
At 30 days, cardiovascular disease has been reported as 
the most frequent cause of death in early-stage NSCLC 
patients (23). In our study, patients with preexisting cardiac 
conditions were more likely to develop cardiac events 
after radiation therapy. Notably, in our patient population 
various comorbidities were more common than in most 
patients who are treated for early-stage lung cancer. 
Therefore most of the patients in our cohort were medical 
inoperable. While the association between cardiac event-
free survival and preexisting heart conditions did not reach 
statistical significance—likely due to insufficient patient 
numbers—there was a clear separation of the Kaplan-Meier 
curves (Figure 2B). Thus, the relation between cardiac dose 
and radiotherapy-related heart toxicity remains unclear 
and further clinical studies are needed to determine how 
much care should be taken to avoid delivering potentially 
detrimental radiotherapy doses to the heart and its 
substructures. This includes assessment of interfraction 
variations of dose delivery to the heart (24). Our findings 
indicate that patients with preexisting heart conditions need 
to be observed with great care as they are at a higher risk 
for cardiac events which might or might not be related to 
SBRT.
Other medical comorbidities
There is evidence that medical comorbidities, particularly 
COPD, play a role in lung cancer mortality (23,27). 
However, the role of comorbidities in early-stage lung 
cancer treated with radiation therapy is a relatively 
unexplored area. In our cohort, we did not identify any 
association between diabetes, high cholesterol, COPD, 
hypertension, smoking status and the development of 
cardiac events. In addition, longer follow-up times might be 
needed to fully characterize cardiac events after SBRT. For 
locally advanced lung cancer, post-radiation therapy cardiac 
events occurred at a median of 26 months after therapy, but 
happened as early as one month (7), whereas in our study 
cardiac events were observed after on average 19 months 
(3–60 months). Therefore, even with rather short follow-up 
times of 35 months on average , early cardiac events can be 
identified.
Limitations
Similar to the other two studies on SBRT and cardiac 
toxicity (18,19), ours is also limited by its retrospective 
nature. Further investigations are needed to determine 
whether radiation dose to the heart or individual 
substructures lead to the development of cardiotoxicity 
and mortality in early-stage lung cancer. Longer follow-
up, larger patient samples, prospective study design and 
contouring of individual cardiac substructures are essential. 
Echocardiography, coronary computed tomography 
and angiography may be helpful to predict which 
patients are likely to develop cardiac events early after 
treatment (26). Radiation-induced cardiac disease was 
reported to be associated with marked thickening, fibrosis 
and narrowing of coronary arteries (28) and by radiation-
induced perfusion defects (29). However, these studies were 
done using standard fractionation radiotherapy and not 
SBRT. Learning more about the mechanism of radiation-
induced heart damage may lead to the development 
of cardioprotective medications, such as possibly ROS 
scavengers, and to the discovery of biomarkers for 
cardiotoxicity (26,30).
Conclusions
Doses to the heart and its substructures show large 
variability and depend on the tumor location in early-
stage lung cancer. New cardiac events after SBRT were 
associated with patients’ history of heart problems. Lung 
cancer patients with preexisting heart conditions need to 
be watched closely as heart disease might affect morbidity 
and potentially influence survival. Longer follow-up times 
and greater patient samples may be needed  to identify 
correlations between comorbidities, radiation technique 
or cardiac radiation doses with cardiac events or overall 
survival. 
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